Literature DB >> 19817676

Therapeutic vaccination and novel strategies to treat chronic HBV infection.

Antonio Bertoletti1, Adam Gehring.   

Abstract

Therapeutic vaccination for the treatment of chronic hepatitis B has so far shown limited clinical efficacy. In this review, we argue that the principal cause of this failure is the profound defect of virus-specific T cells present in chronic hepatitis B patients and we discuss potential new ways to achieve an efficient restoration of virus-specific immunity in patients with chronic hepatitis B virus infection.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19817676     DOI： 10.1586/egh.09.48

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


  20 in total

Review 1.  Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.

Authors:  Adam J Gehring; June Ann D'Angelo
Journal:  Cell Mol Immunol       Date:  2014-11-03       Impact factor: 11.530

2.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Enhanced effect of DNA immunization plus in vivo electroporation with a combination of hepatitis B virus core-PreS1 and S-PreS1 plasmids.

Authors:  Hong Chen; Bo Wen; Yao Deng; Wen Wang; Xiao Yin; Jie Guan; Li Ruan; Wenjie Tan
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

4.  Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.

Authors:  David Gordon; Peter Kelley; Susanne Heinzel; Peter Cooper; Nikolai Petrovsky
Journal:  Vaccine       Date:  2014-09-27       Impact factor: 3.641

5.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

Review 6.  Treatment of hepatitis B virus: an update.

Authors:  Haley Ward; Lydia Tang; Bhawna Poonia; Shyam Kottilil
Journal:  Future Microbiol       Date:  2016-11-18       Impact factor: 3.165

7.  Breaking B and T cell tolerance using cationic lipid--DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV.

Authors:  John D Morrey; Neil E Motter; Stella Chang; Jeffery Fairman
Journal:  Antiviral Res       Date:  2011-04-23       Impact factor: 5.970

8.  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.

Authors:  Danming Zhu; Longchao Liu; Dan Yang; Sherry Fu; Yingjie Bian; Zhichen Sun; Junming He; Lishan Su; Liguo Zhang; Hua Peng; Yang-Xin Fu
Journal:  J Immunol       Date:  2016-03-02       Impact factor: 5.422

9.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.

Authors:  Fadi Saade; Yoshikazu Honda-Okubo; Samay Trec; Nikolai Petrovsky
Journal:  Vaccine       Date:  2013-01-07       Impact factor: 3.641

10.  Strategies to eliminate HBV infection.

Authors:  Rama Kapoor; Shyam Kottilil
Journal:  Future Virol       Date:  2014       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.